Skip to content

MapLight Therapeutics, Inc. MPLT Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.48M+60.0%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$794K-24.5%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-$2.45M+65.1%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$814K-199%
AbbVie logo
AbbVieABBV
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's increase (decrease) in prepaid expense and other assets?
MapLight Therapeutics, Inc. (MPLT) reported increase (decrease) in prepaid expense and other assets of -$2.48M in Q1 2026.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.